Celcuity Inc. (CELC) Stock: Slides 16% as FDA Clears REVTORPYK for Breast Cancer
TLDR Celcuity stock falls 16% despite FDA approval of REVTORPYK for breast cancer. FDA clears REVTORPYK as Celcuity advances targeted cancer treatment plans. CELC shares decline after major approval…
Read the full articleYou might also wanna read
Celcuity (CELC) Secures FDA Approval for Revtorpyk in Breast Cancer Treatment
Related Stocks: CELC
Celcuity wins breast cancer nod, securing ‘differentiated foothold’ in market
Celcuity’s first approved drug, Revtorpyk, is indicated for the second-line treatment of advanced HER2- breast cancer patients without PIK3C
Celcuity Announces FDA Approval of REVTORPYKâ„¢ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
REVTORPYK (gedatolisib) REVTORPYK (gedatolisib) vial and box REVTORPYK is the first and only FDA-approved therapy that inhibits all class I
Celcuity (CELC) Receives FDA Approval for Breakthrough Breast Cancer Treatment
Related Stocks: CELC
US FDA approves Celcuity’s breast cancer drug
By Kunal Das and Christy Santhosh July 14 (Reuters) - The U.S. FDA has approved Celcuity's drug for an advanced form of breast cancer, the r
US FDA approves Celcuity’s breast cancer drug
By Kunal Das and Christy Santhosh July 14 (Reuters) - The U.S. FDA has approved Celcuity's drug for an advanced form of breast cancer, the r
Comments
Sign in to join the conversation.
No comments yet. Be the first.